COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

NEXT STORY
Human Microbiome Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)
PREV STORY
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including ...

author_avatar
NASDAQ Market News

NewLink Genetics Announces Presentation of Two Abstracts at ASCO

AMES, Iowa, April 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)

Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than ...

author_avatar
NASDAQ Market News